Objectives: This study aims to investigate the therapeutic effect of low-dose topical administration of methotrexate (MTX) in a toluene diisocyanate (TDI)-induced allergic rhinitis rat model.
The prevalence of allergic rhinitis (AR) in the general population has been reported to be increasing year by year, and recent research suggested that approximately 20% of the world population is affected by AR. [1] Allergic rhinitis has been described as an inflammatory disorder of the upper airway mucosa, characterized by a local influx of eosinophils. [2] Mast cells express the immunoglobulin Fc epsilon receptor I that triggers specific antigens to immunoglobulin E (IgE). After IgE-dependent stimulation, mast cells release allergic mediators such as histamine, a-hexosaminidase, cytokines, chemokines and arachidonic acid derivatives, mediating acute and chronic inflammation. Therefore, treatment options for AR consist of allergen avoidance, symptomatic treatment and allergen immunotherapy to further improve the control of allergic responses. [1] A better therapeutic agent is required, as the current treatment of AR is limited to antihistamines, nasal corticosteroids, antileukotrienes, and antiallergen immunotherapy. Since these therapies are still not perfect, it is important to continue to study the pharmacology of this disease as part of the search for better drugs. [3] Methotrexate (MTX) is a competitive inhibitor of dihydrofolate reductase, and is a cytotoxic agent widely used for the treatment of malignancy and inflammatory conditions. The inhibition of dihydrofolate reductase, with subsequent impaired thymidylate and DNA synthesis, is the mechanism by which MTX (N-10-methylaminopterin) effects the treatment of cancer. [4] The mechanism of action of MTX as an antiinflammatory and anti-proliferative drug is not fully understood. These effects of MTX are attributed to inhibition of several key enzymes involved in folate, methionine, adenosine and de novo nucleotide synthesis pathways. [5] Methotrexate, used at low dosages to treat a variety of chronic inflammatory diseases, has been proposed to have steroidsparing effects in steroid-dependent asthmatic patients. [6] To our knowledge, there is no study in the literature on the topical application of MTX in the treatment of AR. The aim of the present study was to investigate the therapeutic effect of lowdose topical administration of MTX in a toluene diisocyanate (TDI)-induced AR rat model.
MATERIALS AND METHODS

Subjects and setting:
This study was approved by the "Committee for Ethics in Animal Experiments" of the university (2011-109-407). The experiments were performed on 18 healthy male Wistar albino rats weighing 250-270 g. Animals were maintained on a 12 h light/dark cycle at a constant temperature (22±2°C) with ad libitum access to food and water. The experiments were performed in accordance with the requirements of the "Helsinki Declaration of Research Ethics". Every attempt was made to minimize both the number and suffering of animals used in these experiments. Animals with signs of active or recent nasal infection were discarded. Cephazoline (17 mg/kg, IM) was administered intramuscularly to all rats to reduce the possibility of a bacterial infection confounding experimental results.
Procedure: Parenteral MTX solution (50 mg/mL) was diluted to 0.025 mg/mL concentration, which was placed into a special spray bottle that applied 0.1 mL solution (2.5 µg MTX) with each puff. Sensitization to TDI was performed using the method described by Tanaka et al. [7] Briefly, 10 μL of a 10% solution of TDI (Tıp Kim San, Istanbul, Turkey) in ethyl acetate was painted bilaterally on the nasal vestibules once a day for five consecutive days (sensitization). This sensitization procedure was then repeated after a two-day interval. Allergic rhinitis induced rats were randomly divided into four study groups. All rats were anesthetized with intraperitoneal ketamine (Ketalar ® , Eczacibasi, Turkey; 60 mg/kg) and intraperitoneal xylazine (Alfazyne ® , Alfasan International B.V. Woerden, Holland; 10 mg/kg). All procedures were performed under sterile conditions. The physicians were blinded to the group assignment of the rats. Only the Chief Investigator had access to the randomized code.
Group I (Control group) (n= 5):
No procedure was applied.
Group II (Sham group) (n=3):
Only anesthesia was administered, no drug was applied on the nasal mucosa.
Group III (Steroid group) (n=5):
Mometasone furoate aqueous nasal spray (Nasonex, ScheringPlough Corporation, Istanbul, Turkey) 50 µg was administered topically to both nasal cavities once daily for seven days.
Group IV (MTX group) (n=5):
MTX solution (Methotrexate-Ebewe, Ebewe Pharma, Austria) 0.1 mL was administered topically to both nasal cavities once daily for seven days.
Outcome parameters: After the drugs were administered, the rats were decapitated. The nasal cavities, nasal septa, paranasal sinuses and turbinates were dissected, fixed in 10% buffered formaldehyde and kept in this solution at 4ºC for 24 h. All specimens were dehydrated, embedded in paraffin and serially cut into 5-μm slices. Sections were stained with hematoxylin and eosin for light microscopic examination by a single pathologist.
Biopsies were evaluated histologically for fibrosis, loss of cilia and goblet cells, edema, squamous cell metaplasia, and vascular proliferation. Each parameter was scored between 0 and 3, according to the method of Ercan et al. [8] Tr-ENT ©2018 Behbut Cevanşir Otorhinolaryngology-Head and Neck Surgery Society. All rights reserved.
Open Access using numerical scores (0= no change, 1= mild, 2= moderate, 3= severe).
Statistical analysis
Data was analyzed using the Statistical Package for Social Sciences (SPSS) for Windows version 10.0 software (SPSS Inc., Chicago, IL, USA). All differences associated with a chance probability of 0.05 or less were considered statistically significant. Continuous variables were presented as mean ± standard deviation. Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Histological parameters among groups were compared with independent-sample t test and one-way ANOVA test. for a long time and several studies have been published since then, no firm conclusion has been reached on whether MTX can be considered an alternative or adjuvant drug in AR. In the present study, we attempted to demonstrate whether MTX might be considered as a therapeutic agent in AR.
Although animal models are not always closely reflective of human responses, they can certainly improve our understanding of the cellular and molecular mechanisms associated with TDIinduced allergic disorders. [9] Toluene diisocyanate is capable of inducing different types of immune reactions, depending on T-cell polarization toward the type 1 T helper (Th1) or type 2 T helper (Th2) cells. Th1 cells promote cell-mediated immunity and are defined by their secretion of cytokines, mainly interferon gama (IFN-g). Th 2 cells are recognized by the secretion of interleukins, such as interleukin (IL)-4, IL-5 and IL-13, which support the humoral immune response. In experimental studies, the divergence might be because of different animal experimentation conditions, e.g. sensitization way and dose applied. [10] In the treatment of AR, antihistamines, leukotriene inhibitors, systemic and local steroids, cromolyn sodium, and decongestants can become inadequate except those used as a prophylaxis against allergens. [11] Shimizu et al. [12] used a Th2 cytokine inhibitor suplast tosylate in
RESULTS
Fibrosis, loss of cilia cells, edema, and vascular proliferation were significantly lower in the steroid group than in the control group (p<0.05) ( Table 1 ). There were no statistically significant differences with respect to loss of goblet cells and squamous cell metaplasia between the steroid and control groups (p>0.05).
Fibrosis, loss of cilia cells, edema, and vascular proliferation were significantly lower in the MTX group than in the control group (p<0.05) ( Table 2 ). There were no statistically significant differences with respect to loss of goblet cells and squamous cell metaplasia between the MTX and control groups (p>0.05).
There were no statistically significant differences with respect to histopathological parameters between the steroid group and the MTX group (p>0.05) ( Table 3) .
As the basement membrane thickness did not differ among the study groups and histologically showed "no change" in all rats, this parameter was excluded from statistical evaluation.
DISCUSSION
Although MTX has been a therapy of choice for patients with chronic inflammatory conditions 
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©2018 Behbut Cevanşir Otorhinolaryngology-Head and Neck Surgery Society. All rights reserved. Open Access sensitized rats. Intranasal cyclosporine was used in eosinophilic rhinosinusitis with nasal polyps in a mouse model. [13] Long-term low-dose MTX has been an established treatment for rheumatoid arthritis and Crohn disease since many decades. Other inflammatory disorders including Wegener granulomatosis, sarcoidosis, psoriasis, asthma and atopic dermatitis have also been reported to respond to such treatment. [14] Its mode of action in these conditions has not been fully elucidated, although several mechanisms have been postulated. Methotrexate is a potent inhibitor of the enzyme dihydrofolate reductase, leading to the inhibition of purine and pyrimidine synthesis and reduced T-cell proliferation. Additionally, it is believed that the anti-inflammatory action of MTX stems from the extracellular accumulation of adenosine, which acts as an endogenous antiinflammatory agent. Adenosine binds to specific adenosine receptors and inhibits lymphocyte proliferation as well as the production of the proinflammatory cytokines TNF-a, IL-6, and IL-8, while stimulating transcription of the gene encoding IL-1 receptor antagonist and the production of IL-10. [15] Symptoms of AR are sneezing, nasal rubbing, nasal congestion and rhinorrhea, caused by the interaction between chemical mediators and sensory nerves through activation of specific receptors. Nasal vasodilatation and increased vascular permeability are important features of AR. Angiogenic factor vascular endothelial growth factor (VEGF) has also been shown to increase in the nasal mucosa of patients with AR, as a result of the increase in nasal vascular permeability and congestion. [16] Vascular endothelial growth factor participates in nasal mucosa swelling from increased blood vessel permeability in an immediate reaction of AR. [17] Vascular endothelial growth factor may therefore play an important role in nasal mucosal inflammation in AR. Park et al. [18] showed that MTX decreased levels of VEGF in patients with nasal polyposis. Recently, Buyukozturk et al. [19] described two patients with steroid-dependent asthma whose nasal polyps dramatically decreased in size after a course of MTX therapy, administered as an auxiliary treatment. Corrigan et al. [20] reported that MTX therapy in asthma increases T cell susceptibility to corticosteroid inhibition. Goecke et al. [21] demonstrated that MTX regulates the expression of glucocorticoid receptor alpha and beta isoforms in lymphocytes. Another study supports the use of biological agents in preference to using oral MTX as a steroid-sparing agent at the first instance. [22] A theoretically interesting approach is topical administration of chemotherapy. In a study by Ercan et al., [8] MTX was sprayed topically on the nasal mucosa of rats in various doses for a month. The drug was well tolerated both locally and systemically.
Structural alterations such as ciliary cell loss, epithelial metaplasia, mucous gland hypertrophy, goblet cell hyperplasia, and vascular changes have been reported to occur in patients with AR. These pathologic changes are called tissue remodeling and occur via mediators released from inflammatory cells. [23] In this study using animal AR models, hematoxylin and eosin staining demonstrated ciliary loss in respiratory epithelial cells, and marked vascular proliferation of connective tissue vessels. In the group treated with MTX, and steroids, a decrease in ciliary loss in respiratory epithelial cells, vascular proliferation, edema and fibrosis was observed, and the severity of these changes came close to those seen in the control group. In another study, a higher percentage of goblet cells were determined in patients with nonallergic noninfectious rhinitis. [24] In still another study, no change in the density of goblet cells in biopsy materials retrieved from the inferior nasal turbinate of the patients with perennial rhinitis could be demonstrated. [25] In our study changes in the number of goblet cells did not display a statistically significant difference. In a study performed by Ercan et al. [8] no toxic effect of topical MTX application on nasal mucosa was detected.
Methotrexate can be associated with some side effects, such as oral ulcerations, nausea, diarrhea, post dose reactions like arthralgia, fatigue, and less commonly abnormal liver function tests and myelosuppression. Most of these side effects, including myelosuppression, are dose dependent and occur infrequently at the doses typically used in non-malignant diseases. [26] 
